This is a routine procedural ruling with no material impact on PFE's stock. The underlying patent litigation continues on schedule. Monitor for claim construction rulings or summary judgment motions later in 2026, which could shift settlement leverage.
PFE drugs
PFE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 17 $25.47entry
- T+1 · 5mo ago −2.74%α −3.78% · $24.78
- T+5 · 5mo ago −8.68%α −8.04% · $23.26
- T+20 · 4mo ago −3.36%α −3.93% · $24.62
- T+60 · 2mo ago +8.82%α +5.86% · $27.72
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A Special Master in the District of Delaware denied GSK's motion to limit Pfizer/BioNTech and Moderna to a combined 10 hours of deposition time for two key inventor witnesses in related patent infringement cases against PFE and MRNA. The ruling preserves each defendant group's full 7-hour deposition entitlement per witness, meaning PFE/BioNTech can conduct independent, uncoordinated depositions of Drs. Geall and Mandl without sharing time with Moderna. This is a procedural discovery ruling with no financial exposure, it keeps the litigation on its current schedule and does not change the merits of the patent claims against PFE.
Court Ruling Details
Key Facts
- Special Master denied GSK's motion to limit PBNT and Moderna to a combined 10 hours of deposition time for two key inventor witnesses (Drs. Geall and Mandl).
- Each defendant group retains the full 7-hour deposition entitlement per witness under Fed. R. Civ. P. 30(d)(1).
- The ruling does not require PBNT and Moderna to coordinate questioning or attend each other's depositions.
- Fact discovery closes July 29, 2026, the ruling keeps the existing schedule intact.
- No damages, injunction, or financial exposure was awarded or altered by this ruling.
Financial Impact
No financial impact, procedural discovery ruling only.
Risk Factors
- No new risks from this ruling, the patent litigation remains an ongoing overhang but this order does not change its trajectory.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-3rrqn0ol-PFE |
Track record
21 reports on PFE
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +17.28% at T+60 after the Aug 4, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $30.79 Now $28.86 −6.27% settles Feb 2
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $30.00 Now $28.86 −3.80% settles Feb 1
- Oct 30, 202618d ago Court Ruling Neutral 2/10 Entry $30.67 Now $28.86 −5.90% settles Jan 29
- Oct 23, 202624d ago Institutional Cluster Mixed 3/10 Entry $30.03 Now $28.86 −3.90% settles Jan 21
- Aug 13, 202613w ago Court Ruling Neutral 1/10 Entry $26.79 to $29.23 Now $28.86 +7.73% ▲ +9.11% +12.15% vs SPY
- Aug 12, 202613w ago Insider Buy Bullish 5/10 Entry $26.80 to $29.39 Now $28.86 +7.69% ▲ +9.66% +15.14% vs SPY
- Aug 12, 202613w ago Insider Cluster Bullish 6/10 Entry $26.80 to $29.39 Now $28.86 +7.69% ▲ +9.66% +15.14% vs SPY
- Aug 6, 202614w ago Insider Cluster Bullish 4/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
- Aug 5, 202614w ago Insider Buy Bullish 5/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
- Aug 5, 202614w ago Insider Cluster Neutral 3/10 Entry $26.20 to $30.52 Now $28.86 +10.15% ▲ +16.49% +18.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers